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Background: We studied whether the sinuses might be foci for Pseudomonas aeruginosa lung infection.
Methods: Endoscopic Sinus Surgery was performed in 78 CF patients; PFGE was used for bacterial genotyping. Material from sinuses and lungs
were Gram-stained to detect bioﬁlms. Immunoglobulins were measured in serum and saliva.
Results: When P. aeruginosa was cultured simultaneously from the sinuses and the lungs they were genetically identical in 38 of the 40 patients
(95%). In the sinuses, P. aeruginosa formed bioﬁlms with minimal cellular inﬂammation, probably because of a signiﬁcantly higher local
production of secretory IgA compared with IgG (pb0.001).
Conclusions:We have shown that P. aeruginosa form bioﬁlm in the sinuses, which constitute an important bacterial reservoir for subsequent lung
infection. The high amount of IgA in the upper airways probably protects P. aeruginosa from the inﬂammatory immune system, and they can
proceed unnoticed into a permanent infectious focus that cannot be eradicated with antibiotics.
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The most common manifestations of cystic fibrosis (CF) are
pulmonary disease, radio-opaque sinuses, nasal polyposis and
exocrine pancreatic insufficiency. Symptoms of chronic rhino-
sinusitis have been reported in 11–94% of CF patients [1].
Sinusitis is seldom recognised by the patients but nearly all CF
patients have radiographic and clinical signs of infection [1,2].
Molecular epidemiology studies have shown that CF lung
transplant recipients become re-colonised in their lung grafts with
the same clones as those cultured before transplantation [3]. It is
likely that Pseudomonas aeruginosa is drained into the lung
allografts from a bacterial reservoir in the paranasal sinuses via
the airways [3,4]. In lung transplanted CF patients sinus surgery
aiming at eradication of bacteria, mostly P. aeruginosa, hasby Elsevier B.V. All rights reserved.
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transplantation [5].
We have previously genotyped initial and subsequent
P. aeruginosa lung isolates from CF patients by using Array
Tube biochip analysis (Clondiag®), a method based on single
nucleotide polymorphisms (SNPs) [6] and by Pulsed Field Gel
Electrophoresis (PFGE) [6]. We found that the initial colonising
P. aeruginosa strains had different genotypes; i.e. every patient
had a genotype different from all other patients. This suggests that
the initial colonisation comes from environmental sources rather
than from transmission between patients [7]. We also found that
new lung colonising isolates had the same genotype as the initial
colonising strain after antibiotic eradication of P. aeruginosa,
suggesting a bacterial reservoir either in the patient or in the
patient's close environment [6].
In the present prospective study, we examined whether the
paranasal sinuses serve as a bacterial reservoir for CF pathogens,
especially P. aeruginosa, leading to reinfections with the same
genotype as the initial infection. We cultured and genotyped
historical isolates as well as paired P. aeruginosa isolates from
sputum and sinuses from children and adults with CF who
underwent Functional Endoscopic Sinus Surgery (FESS) to see if
bacteria from the two anatomical locations were identical.
2. Materials and methods
2.1. General care
300 CF patients are followed at the Danish CF centre,
Copenhagen [8,9] and treated according to fixed guidelines [8].
Intermittent colonisation: Patients with at least one isolate of
P. aeruginosa, but normal levels of precipitating antibodies
against P. aeruginosa ( 0–1 precipitins) [8].
Chronic P. aeruginosa lung infection: Growth of P. aeruginosa
in six consecutive monthly sputum samples, or less if there are two
or more precipitating antibodies against P. aeruginosa [8].
2.2. Bacteria
Since 1973, we have collected and stored (−80 °C)
P. aeruginosa sputum isolates sequentially [8,9].
2.3. Included patients
Seventy-eight CF patients N6 years (median 19 years, range
6–50), (29 males, 49 females) were treated with FESS between
January 27, 2007 and April 1, 2010.
There are no guidelines for sinus surgery in CF patients [10].
Patients were selected based on one or more of the following
criteria: 1) intermittent colonisation with declining lung
function despite intensive antibiotic therapy and/or increasing
antibodies against Gram-negative bacteria e.g. P. aeruginosa,
Achromobacter xylosoxidans or Burkholderia cepacia complex,
2) lung transplantation within the last year, and 3) severe
symptoms of rhinosinusitis according to the European Position
Paper guidelines (EPOS) [10]. The majority fulfilled the first
and third criterion.2.4. Functional Endoscopic Sinus Surgery (FESS)
FESS created ventilation and drainage pathways to and from
the sinuses, making the paranasal sinuses accessible for
irrigations [11].
An average of six tissue or pus samples (range 1–14) was
taken from each patient. The FESS was finalised by sinus
irrigation applying 3 MIE polymyxin E (colistin).
A sputum sample was obtained on the same day as the
surgery to compare bacteriology in the lungs with the sinuses.
After surgery, the majority of patients did nasal irrigations
with colistin twice daily for at least 6 months. An ENT specialist
performed postoperative follow-up five times during the first year
after surgery.
2.5. Bacteriology and typing methods (PFGE)
Gram-stained smears for biofilm detection, and aerobic and
anaerobic cultures at 37 °C on standard agar media for 5–7 days,
were carried out on all tissue and pus samples [9,12]. PFGE was
used for genotyping P. aeruginosa isolates from the sinuses and
the lungs [9].
2.6. Serum and saliva
Serum and saliva were collected from 25 randomly chosen
FESS patients who were either intermittently colonised or
chronically infected with P. aeruginosa. Saliva was obtained
by using four sterile 6 mm diameter paper discs (Antibiotica
Testblættchen, Struers, Denmark) that were placed on the
mouth mucosa for 30 sec. The saliva-soaked discs were stored
at −80 °C until analysed.
2.7. IgG and IgA antibodies against P. aeruginosa in saliva
and serum
Specific antibodies were measured using ELISA [13,14].
The volume of all reagents for the serum ELISA was 100 μl,
but 50 μl for the saliva ELISA. Phosphate-buffered saline (PBS
pH 7.2)+0.1% Tween-20 (Sigma)+NaCl 15 g/l (= dilution
buffer) were used for all washing steps and the plates were
washed three times.
Saliva-impregnated paper-discs were incubated on a shaker
for one hour at 35 °C in 175 μl dilution buffer to elute IgG and
IgA antibodies.
Antibodies against alginate, 96-well microtiter plates (Mikro-
well, BiotechLine A/S, Denmark) were coated with alginate
(10 μg/ml) purified from a mucoid CF P. aeruginosa strain
(6680NH). The plates were coated over night at 35 °C and
blocked for one hour at 35 °C in dilution buffer. Serum was
diluted 1:4,000 and saliva was already diluted 1:8 in the elution
procedure and used without further dilution for detection of IgA
and IgG. After washing, horseradish peroxidase (HRP)-conjugate
(DakoA/S, Glostrup, Denmark) detecting IgG and IgA antibodies
were added for one hour. The detecting antibodies were rabbit
anti-human IgG (γ-chain-specific) diluted 1:10,000 or rabbit anti-
human IgA (α-chain-specific) diluted 1:10,000.
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cated cell extract of P. aeruginosa serogroups 1–17) were used
as standard antigen (protein concentration 16 mg/ml). The antigen
was coated onto irrigated 96-well polysterene plates (Maxisorb,
BiotechLine A/S, Denmark) at a dilution of 1:2,000. The plates
were incubated for one hour at 35 °C and blocked overnight with
dilution buffer at 4 °C. Serumwas diluted 1:100 and saliva 1:8 for
detection of IgG and IgA and allowed to react for one hour at
35 °C. After washing, horseradish peroxidase (HRP)-conjugate
diluted 1:20,000 (Dako A/S, Glostrup, Denmark) detecting IgG
(P0214) and IgA (P0216) antibodies in serum and saliva were
added for one hour. The peroxidase-conjugated second antibodies
were as described above.
TMB Plus was added (KemEnTec Diagnostics). The reaction
was stopped after one hour by 1 M H2SO4. The absorbance
was measured at 450 nm on a plate reader (Multiscan EX, Bie
& Berntsen, Denmark). The results were expressed as optical
density values (OD).
2.8. Ethics
The study was approved by the local ethics committee,
Region Hovedstaden, (H-A-141) and all patients gave informed
consent.
2.9. Statistics
Within-patients samples of serum and saliva antibodies were
compared using the sign test.
3. Results
Thirty-two of the 78 patients were chronically infected; 21
with P. aeruginosa (median age 31 years, range 12–50 years),
5 with A. xylosoxidans, 4 with B. multivorans complex and 2
with Stenotrophomonas maltophilia. The remaining 46 patients
were intermittently colonised; 31 with P. aeruginosa (median
age 14 years, range 7–29 years), 6 with A. xylosoxidans and 9
with other CF pathogens such as Haemophilus influenzae,
Staphylococcus aureus or Streptococcus pneumoniae in their
lungs.
Of the 21 patients chronically infected with P. aeruginosa,
18 (86%) had simultaneous growth of P. aeruginosa in their
sinuses and lower airways; this was also the case for all 5
patients with growth of A. xylosoxidans, all 4 with growth of
B. multivorans complex, whereas none of the 2 patients with
chronic S. maltophilia infection in their lungs had growth of
this bacterium in their sinuses.
In 22 of the 31 (71%) intermittently colonised patients, we
cultured P. aeruginosa from both the sinuses and lungs.
We did not detect any anaerobic microorganisms in any of
the sinuses although the cultures were performed less than one
hour after the sinus samples were taken and incubation was
performed for 7 days.
PFGE patterns were used to compare the relatedness
of sequentially collected P. aeruginosa lung isolates with
P. aeruginosa cultured from the lungs and sinuses after FESS.In 18 of the 18 patients (100%) with chronic P. aeruginosa lung
infection and from whom we had simultaneous growth of
P. aeruginosa in their sinuses and lungs, P. aeruginosa was
genetically identical. We found that chronically infected
patients had the same P. aeruginosa genotype in the lungs for
a median of 15 years similar to the P. aeruginosa that were
cultured in the sinuses (range 1–29 years). We found that 5 of
the 18 patients had identical genotypes in their lungs for more
than 20 years and this was the same genotype as cultured from
the sinuses after FESS.
Twenty of the 22 (91%) intermittently colonised patients
with P. aeruginosa in their sinuses had PFGE identical isolates
in their lungs, whereas a different genotype was found in two
patients. Patients who had identical P. aeruginosa in their lungs
and sinuses at the time of surgery had a similar genotype in
their lungs for a median of 3.5 years (range 1–6 years).
Gram-stained smears from the sinuses showed that all
patients chronically infected with P. aeruginosa had their
bacteria organised in biofilm-like structures similar to what is
seen in the lungs of the patients [15,16] (Fig. 1 a–f). When
microscopically analysing Gram-stained smears from the lung
and sinuses obtained on the same day in patients chronically
infected with P. aeruginosa, we found that bacterial biofilms in
the lung were surrounded by a large number of inflammatory
cells, predominantly polymorphonuclear cells (PMNs), whereas
only very few and scattered PMNs were seen in the surroundings
of the sinus biofilms (Fig. 1 b, d, f). In addition, we found that
patients with chronic A. xylosoxidans and B. cepacia complex
infection also had their bacteria organised in aggregates in the
sinuses [17].
None of the 21 patients chronically infected with P. aeruginosa
had the bacteria eradicated from the lungs following FESS. In
intermittently colonised patients (N=31) the median time from
sinus surgery to regrowth of P. aeruginosa in sputum was
7.3 months. In patients who had P. aeruginosa cultured from their
sinuses (N=22), P. aeruginosa was cultured again from the lungs
5.3 months after FESS.
Saliva IgA against P. aeruginosa sonicate (median optical
density (OD) 83) and alginate (median OD 186) was 15 and 39
times higher than serum IgA (median OD 5 in both cases)
(pb0.001 in both cases), indicating a local production of IgA in
the upper airways. The IgA antibody levels in saliva against
P. aeruginosa sonicate and alginate were also significantly
higher than the saliva IgG production (median OD 2 and 0,
respectively) (pb0.001 in both cases). The IgG levels in serum
against P. aeruginosa sonicate and alginate were also low
(median OD 3 in both cases).
4. Discussion
We have performed the largest published study till now of
invasive sinus surgery investigating the possible role of the
sinuses as a reservoir for bacterial adaptation and repeated
colonisation and infection of the lungs [3,18,19]. The group of
intermittently colonised patients, which we included in this study,
is a selected subgroup among our children population since most




Fig. 1. a–f. Microscopic investigation of Gram-stained smears of pus from the sinuses (a, c and e) and corresponding sputum (b, d and f) obtained from three patients
chronically infected with P. aeruginosa at the time of sinus surgery, magnification ×1000. Arrows indicate biofilms.
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constitutes 24% of the overall intermittently colonised chil-
dren population [20] whereas most of our children have been
recolonised with a different genotype after successful eradication
[20]. This is in agreement with the data reported by Taccetti et al.
[21] and Munck et al. [22], who found that 73% and 74% of their
patients had a different P. aeruginosa genotype in their lungs
when recolonised.
In chronically infected patients we found 100%genetic identity
between P. aeruginosa in the sinuses and lungs. In intermittentlycolonised patients, we found concordant bacteriology in the
sinuses and lungs and in 91% of these patients we found identical
P. aeruginosa genotypes. We also found that the same genotype
had been colonising the lungs intermittently for up to 6 years prior
to the FESS, although the bacteria apparently had been eradicated
by antibiotic therapy every time they were cultured from the
patients' sputum. This paradox challenges the current definition
of intermittent colonisation versus chronic infection. We define
chronic P. aeruginosa infection as continued presence of the
bacteria in the lungs over a period of at least 6 months and/or
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P. aeruginosa, whereas intermittent colonisation is defined as
isolation of P. aeruginosa in a patient with no measurable
antibodies in the blood (normal: 0–1 precipitins) and no clinical
symptoms [8]. The intermittently colonised patients that have had
sinus surgery in this article have been colonised with the same
genotype for a median of 3.5 years with no measurable antibody
responses and therefore need to be classified into a new group of
chronically colonised patients. If the same clone of P. aeruginosa
persists for such long periods of time it should be considered
chronic despite the lack of precipitating antibodies. We therefore
need to modify our operational definition of chronic infection.
All patients chronically infected with P. aeruginosa in their
lungs and from whom we cultured P. aeruginosa in the sinuses
harbored identical clones. A small subgroup of patients who
underwent FESS had the same genotype in their sinuses and
lungs for more than two decades. This is in accordance with the
findings byMainz et al. [23] who in a cross-sectional study found
that 95% of the P. aeruginosa isolates from 24 patients had
identical SNP-genotypes in both compartments, indicating that
the upper airways play a role as a reservoir of P. aeruginosa in
CF, and by Muhlenbach et al. [24] who demonstrated identical
genotypes in the upper and lower airways in 83% of samples
obtained from twelve patients.
Our study shows that the adaptation of P. aeruginosa to the
sinuses is different from the adaptation in the lungs. In the lungs
there is a PMN dominated inflammation with release of oxygen
radicals [25], probably because the lungs, especially the respi-
ratory zone, contain high levels of IgG against P. aeruginosa,
which promotes an inflammation dominated by PMNs. In the
sinuses, we did not find a similar PMN-dominated inflammation
but a high level of IgA compared to IgG, and IgA has non-
inflammatory properties and inhibit the PMN recruitment [26].
The immunoglobulin distributions fit well with a recent study by
Schraven et al. showing that the number of plasma cells in CF
patients with chronic polypoid sinusitis was significantly elevated
compared to non-CF patients and that the number of neutrophils
were low in both groups [27].We have previously found that there
is a common mucosal secretory IgA response to P. aeruginosa in
CF patients, whereas the systemic response is dominated by IgG
[28]. The secretory IgA response, both to the biofilm matrix-
component alginate and to the P. aeruginosa sonicate, including
proteins and LPS, implies that the P. aeruginosa sinusitis is rather
silent because of the lack of PMNs compared with the chronic
lung infection [16] and that P. aeruginosa may adapt to the
chronic life-style and be well suited for causing lung infections
especially if adaptation and biofilm formation has begun in the
sinuses [11,20]. Although we cannot totally exclude that specific
subpopulations of bacteria from the lungs are transmitted to the
sinuses from time to time our previous results suggest that the
direction of migration is mainly downwards at the early stages of
infection [20]. None of the intermittently colonised patients had
elevated precipitating antibodies against P. aeruginosa before
surgery, which supports our hypothesis that the bacteria in the
sinuses are not being recognised by the systemic immune system
(IgG antibodies) but by the mucosal immune system (secretory
IgA) [28]. In chronically infected patients we found thatP. aeruginosa also forms biofilms in the sinuses similar to the
biofilms in the lungs. However, there is an important difference.
There are only very few PMNs around the biofilm in the sinuses in
contrast to the significant amount of PMNs surrounding the
biofilms in the lungs and this is, probably due to the non-
inflammatory secretory IgA response (Fig. 1a–f) [16].
We have previously demonstrated that many CF patients in
our clinic contracted their initial P. aeruginosa colonisation and
chronic lung infection during the viral season in the winter
months (October to March) [29]. When patients have a viral
infection, the excessive secretions formed in the upper respiratory
tract become liquid, and will easily find its way into the deepest
portion of the lungs within minutes [30]. When P. aeruginosa
containing secretions in the sinuses of CF patients become
liquefied, they may easily enter the lungs by aspiration and
become difficult to clear. Accumulation of bacteria-laden liquid
in the supralaryngeal portion during viral infection may by
aspiration overwhelm the mucociliary defense mechanisms of the
sub-laryngeal portion, and the secretions are aspirated especially
during sleep [30]. When bacteria from the sinuses are aspirated
into the lungs they might be pre-adapted and therefore less
virulent compared with environmental P. aeruginosa isolates,
since they have had the opportunity to evolve to the lifestyle in
the lungs [20,31]. The sinuses can be seen as an “evolutionary
nest” where bacteria are diversifying, develop antibiotic resis-
tance and other phenotypes associated with adaptation to the CF
airways in general [20].
In intermittently colonised patients the overall duration until
regrowth of P. aeruginosa in the sputum after FESS was
7 months whereas the median time to recurrence ofP. aeruginosa
in sputum in patients from whom we cultured P. aeruginosa in
their sinuses was less than half a year. We believe that the FESS
procedure itself cannot keep the children free ofP. aeruginosa for
a prolonged period of time but has to be carried out together with
other postoperative treatment such as nasal irrigation with colistin
and inhaled intravenous antibiotics. This is in agreement with a
recent trial in CF patients assessing 0.9% NaCl versus dornase
alpha delivered by vibrating aerosols into the paranasal sinuses
[32]. Dornase alpha inhalation was associated with a significantly
improved quality of life score. In the future such therapeutic
approaches with simultaneously dornase alpha and sinonasal
inhalation of antibiotics might benefit patients where FESS is not
an option.
There are some limitations in our study that should be
considered when interpreting the results. We could not culture
any anaerobic microorganisms in the sinuses although this was
expected based on our previous findings [11]. It could be due to
the intensive antibiotic treatment of these patients or insufficient
handling of the samples, although they were cultured within one
hour after surgery [8,12]. In addition, we expected to find an even
higher number of patients with matching P. aeruginosa in their
sinuses and lungs, but there might have been too few bacteria
in our samples. Molecular based methods may have been
appropriate, but this would not have given any information on
genotypes.
In conclusion, we have shown that the sinuses are bacterial foci
for P. aeruginosa in CF patients. In the sinuses, P. aeruginosa
530 H.K. Johansen et al. / Journal of Cystic Fibrosis 11 (2012) 525–531grow in biofilms that are similar to the biofilms seen in the lungs
of chronically infected patients. In contrast to the situation in the
lungs, a high concentration of non-inflammatory secretory IgA in
the sinuses probably impedes the PMNs from being recruited,
which may prevent local and systemic inflammation and
recognition of microorganisms, contributing to adaptation and
persistence of P. aeruginosa ready to colonise and infect the
lungs.
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